Brazil grants emergency approval to J&J COVID vaccine

COVID-19 vaccine
Credit: Pixabay/CC0 Public Domain

Brazil approved Johnson & Johnson's single-dose COVID-19 vaccine for emergency use Wednesday, the fourth vaccine to get regulatory approval in the hard-hit country.

Federal health regulator Anvisa said its board had unanimously approved the vaccine for use on priority groups such as health providers and the elderly.

Brazil signed a deal with the US pharmaceutical giant two weeks ago for 38 million doses of the vaccine, but they will only start arriving in August.

The South American country is struggling to secure enough to immunize its 212 million people, even as an explosion of COVID-19 pushes hospitals to the .

Brazil also has a deal with Pfizer for 100 million doses, due to start arriving between April and May.

Brazil is currently applying two vaccines, Oxford/AstraZeneca's and Chinese-developed CoronaVac, both of which require two doses.

With just eight percent of the population having received a first dose and 2.3 percent a second, the country is far off pace to meet the 's goal of immunizing all adults by the end of the year.

That has fueled criticism of far-right President Jair Bolsonaro, who has downplayed the coronavirus threat, refused to purchase various vaccines and said he does not plan to be vaccinated himself.

COVID-19 has claimed more than 321,000 lives in Brazil, second only to the United States, and only shows signs of intensifying until enough vaccines arrive.

Brazil's average daily death toll has more than quadrupled since the start of the year, to 2,976 this week, the highest by far worldwide.

March was Brazil's deadliest month in the pandemic yet by a long shot, with 66,573 people killed by COVID-19, according to health ministry figures.

That was more than double its previous record of 32,881 deaths in July 2020.

Explore further

Follow the latest news on the coronavirus (COVID-19) outbreak

© 2021 AFP

Citation: Brazil grants emergency approval to J&J COVID vaccine (2021, April 1) retrieved 8 August 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors